Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

R8404

Sigma-Aldrich

Rufinamide

≥98% (HPLC), powder

Synonyme(s) :

1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-Triazole-4-carboxamide

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C10H8F2N4O
Numéro CAS:
106308-44-5
Poids moléculaire :
238.19
Numéro MDL:
MFCD00865314
Code UNSPSC :
12352200
ID de substance PubChem :
24724595
Nomenclature NACRES :
NA.77

Niveau de qualité

100

Pureté

≥98% (HPLC)

Forme

powder

Couleur

white

Solubilité

DMSO: 9 mg/mL

Auteur

Novartis

Température de stockage

−20°C

Chaîne SMILES 

NC(=O)c1cn(Cc2c(F)cccc2F)nn1

InChI

1S/C10H8F2N4O/c11-7-2-1-3-8(12)6(7)4-16-5-9(10(13)17)14-15-16/h1-3,5H,4H2,(H2,13,17)

Clé InChI

POGQSBRIGCQNEG-UHFFFAOYSA-N

Informations sur le gène

human ... SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Application

Rufinamide has been used to test its analgesic effect on neuropathic pain in spared nerve injury (SNI) model.

Actions biochimiques/physiologiques

Rufinamide may elicit inhibition of the sodium channels and block action potential generation. This property makes it an antiepileptic drug for treating epilepsy disorders like Lennox-Gastaut syndrome.
Broad-spectrum anticonvulsant.

Caractéristiques et avantages

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Implications diagnostiques

Effective therapy for partial seizures in adults and childhood seizures in Lennox-Gastaut syndrome.

Pictogrammes

Health hazardExclamation mark
GHS08,GHS07

Mention d'avertissement

Warning

Mentions de danger

H336,H351,H361fd

Classification des risques

Carc. 2 - Repr. 2 - STOT SE 3

Organes cibles

Central nervous system

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 7

1 of 7

Lacosamide solution 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

L-029

Lacosamide solution

vibrant-m

Y0001982

Lacosamide

Levetiracetam ≥98% (HPLC)

Sigma-Aldrich

L8668

Levetiracetam

Teriflunomide ≥98% (HPLC)

Sigma-Aldrich

SML0936

Teriflunomide

Retigabine analytical standard

Supelco

90221

Retigabine

Gabapentin solid

Sigma-Aldrich

G154

Gabapentin

Streptavidine Sepharose™ haute performance Cytiva 17-5113-01, pack of 5 mL

GE17-5113-01

Streptavidine Sepharose™ haute performance

Shahin Hakimian et al.
Expert opinion on pharmacotherapy, 8(12), 1931-1940 (2007-08-19)
Rufinamide (1-[2,6-difluorobenzyl]-1H-1,2,3-triazole-4-carboxamide) is a new anti-epileptic drug with a novel triazole derivative structure. The suspected mechanism of action is limitation of sodium-dependent action potentials, thought to result in a membrane stabilizing effect. Rufinamide is extensively metabolized in the liver by
C von Stülpnagel et al.
European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 16(5), 459-463 (2012-01-24)
We evaluated the long-term efficacy and tolerability of the orphan drug rufinamide (RUF) in children with pharmacoresistant myoclonic-astatic epilepsy (MAE, Doose syndrome). This was a retrospective European multicenter study on eight patients who had started an intention-to-treat trial of RUF
Isabelle Mourand et al.
Epilepsia, 54(1), e5-e8 (2012-07-12)
Rufinamide (RUF) is a novel antiepileptic drug considered as second-line therapy in the treatment of Lennox-Gastaut syndrome. Treatment-emergent adverse events (AEs) have consisted mainly of drowsiness, irritability, vomiting, and loss of appetite. RUF is considered as a "weight-neutral" drug. We
Alberto Verrotti et al.
Pediatric neurology, 44(5), 347-349 (2011-04-13)
Rufinamide is a new orally active antiepileptic drug that has been found to be effective in the treatment of partial seizures and drop attacks associated with Lennox-Gastaut syndrome. We performed a quantitative analysis of the efficacy of this new antiepileptic
Maria G Dahlin et al.
Neuropediatrics, 43(5), 264-270 (2012-09-04)
We examined the influence of age and type of concomitant antiepileptic drugs (AEDs) on the pharmacokinetics of rufinamide (RUF) as well as its efficacy and safety in 51 children with refractory epilepsy. In a retrospective noninterventional survey, dose-to-concentration ratios of
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique